Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Plain-language summary
This trial is testing Biopsy for patients with anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (CTCL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Biopsy (PROCEDURE): Undergo tumor biopsy | Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy | Computed Tomography (PROCEDURE): Undergo SPECT/CT | Positron Emission Tomography (PROCEDURE): Undergo PET scan | Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter (BIOLOGICAL): Given IV | Single Photon Emission Computed Tomography (PROCEDURE): Undergo SPECT/CT | Cemiplimab (BIOLOGICAL): Given IV | Ruxolitinib (DRUG): Given PO
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details